p63 and p73: Roles in Development and Tumor Formation
Open accessThe DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Abstract
The tumor suppressor p53 is critically important in the cellular damage response and is the founding member of a family of proteins. All three genes regulate cell cycle and apoptosis after DNA damage. However, despite a remarkable structural and partly functional similarity among p53, p63, and p73, mouse knockout studies revealed an unexpected functional diversity among them. p63 and p73 knockouts exhibit severe developmental abnormalities but no increased cancer susceptibility, whereas this picture is reversed for p53 knockouts. Neither p63 nor p73 is the target of inactivating mutations in human cancers. Genomic organization is more complex in p63 and p73, largely the result of an alternative internal promoter generating NH2-terminally deleted dominant-negative proteins that engage in inhibitory circuits within the family. Deregulated dominant-negative p73 isoforms might play an active oncogenic role in some human cancers. Moreover, COOH-terminal extensions specific for p63 and p73 enable further unique protein-protein interactions with regulatory pathways involved in development, differentiation, proliferation, and damage response. Thus, p53 family proteins take on functions within a wide biological spectrum stretching from development (p63 and p73), DNA damage response via apoptosis and cell cycle arrest (p53, TAp63, and TAp73), chemosensitivity of tumors (p53 and TAp73), and immortalization and oncogenesis (ΔNp73).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These families do not have a Li-Fraumeni phenotype or a high cancer incidence, and somatic mutations in cancers contain few if any p63 or p73 mutations”
From The Origins and Evolution of the p53 Family of Genes (2010) · cites this paper as Moll and Slade 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: p73α Regulation by Chk1 in Response to DNA Damage
Gonzalez, S., Prives, C., & Cordon-Cardo, C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8161-8171.2003 · Cited by 75
RetractedVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
p63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“p53 has an important developmental role in early mouse embryogenesis (E7-8d) as revealed when the autoregulatory feedback loop with MDM2 is removed and p53 levels remain uncontrolled (40, 41).”
Backgroundp63 identifies keratinocyte stem cells
Pellegrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., Ponzin, D., McKeon, F., & De Luca, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061032098 · Cited by 1,363
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1×
“p53 has an important developmental role in early mouse embryogenesis (E7-8d) as revealed when the autoregulatory feedback loop with MDM2 is removed and p53 levels remain uncontrolled (40, 41).”
BackgroundYang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., & Jacks, T. (2002) · Nature · doi:10.1038/416560a · Cited by 802
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
Field, S. J., Tsai, F.-Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Livingston, D. M., Orkin, S. H., & Greenberg, M. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81255-6 · Cited by 754
Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome
Celli, J., Duijf, P., Hamel, B. C. J., Bamshad, M., Kramer, B., Smits, A. P. T., Newbury-Ecob, R., Hennekam, R. C. M., Van Buggenhout, G., van Haeringen, A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81646-3 · Cited by 713
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1
Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., & Dyson, N. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81254-4 · Cited by 698
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664 · cited 1×
“The ankyrin-rich, Src holomogy 3 domain, proline-rich proteins ASPP1 and ASPP2 stimulate the apoptotic function of p53, p63, and p73 (77, 78).”
Backgroundp63 is the molecular switch for initiation of an epithelial stratification program
Koster, M. I., Kim, S., Mills, A. A., DeMayo, F. J., & Roop, D. R. (2004) · Genes & Development · doi:10.1101/gad.1165104 · Cited by 622
p63 expression profiles in human normal and tumor tissues.
Como, C. J. D., Urist, M. J., Babayan, I., Drobnjak, M., Hedvat, C. V., Teruya‐Feldstein, J., Kamal, P., Hoos, A., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 579
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Interaction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Cloning and functional analysis of human p51, which structurally and functionally resembles p53
Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., et al. (1998) · Nature Medicine · doi:10.1038/nm0798-839 · Cited by 529
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
An Anti-Apoptotic Role for the p53 Family Member, p73, During Developmental Neuron Death
Pozniak, C. D., Radinovic, S., Yang, A., McKeon, F., Kaplan, D. R., & Miller, F. D. (2000) · Science · doi:10.1126/science.289.5477.304 · Cited by 465
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
AIS is an oncogene amplified in squamous cell carcinoma
Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., & Sidransky, D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5462 · Cited by 463
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
Self-citationp73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408
Association of p63 with Proliferative Potential in Normal and Neoplastic Human Keratinocytes
Parsa, R., Yang, A., McKeon, F., & Green, H. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00780.x · Cited by 407
Covalent Modification of p73α by SUMO-1
Minty, A., Dumont, X., Kaghad, M., & Caput, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004293200 · Cited by 388
The potential tumor suppressor p73 differentially regulates cellular p53 target genes.
Zhu, J., Jiang, J., Zhou, W., & Chen, X. (1998) · PubMed · Cited by 378
Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity
De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M., & Melino, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1763 · Cited by 368
Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., & Gu, W. (2003) · Cell · doi:10.1016/s0092-8674(02)01255-2 · Cited by 356
Role of the p53-homologue p73 in E2F1-induced apoptosis
Stiewe, T., & Pützer, B. M. (2000) · Nature Genetics · doi:10.1038/82617 · Cited by 354
Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53
Grob, T. J., Novak, U., Maisse, C., Barcaroli, D., Lüthi, A. U., Pirnia, F., Hügli, B., Graber, H. U., De Laurenzi, V, Fey, M. F., et al. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400962 · Cited by 341
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334 · cited 2×
“MDM2 is transcriptionally activated by p73 and in turn negatively regulates the transcriptional ability of p73, just as it functions toward p53 (67, 72, 73).”
BackgroundA common E2F-1 and p73 pathway mediates cell death induced by TCR activation
Lissy, N. A., Davis, P. K., Irwin, M., Kaelin, W. G., & Dowdy, S. F. (2000) · Nature · doi:10.1038/35036608 · Cited by 330
Westfall, M. D., Mays, D. J., Sniezek, J. C., & Pietenpol, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2264-2276.2003 · Cited by 330
DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 319
ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 318
Self-citationA novel protein with strong homology to the tumor suppressor p53
Schmale, H., & Bamberger, C. (1997) · Oncogene · doi:10.1038/sj.onc.1201500 · Cited by 283
Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 280
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
Unger, T., Nau, M. M., Segal, S., & Minna, J. D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05183.x · Cited by 261
Down-regulation of p63 is required for epidermal UV-B-induced apoptosis.
Liefer, K. M., Koster, M. I., Wang, X., Yang, A., McKeon, F., & Roop, D. R. (2000) · PubMed · Cited by 260
Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer
Urist, M. J., Di Como, C. J., Lu, M.-L., Charytonowicz, E., Verbel, D., Crum, C. P., Ince, T. A., McKeon, F. D., & Cordon-Cardo, C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64396-9 · Cited by 257
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 240
Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., & Sidransky, D. (1998) · Nature Medicine · doi:10.1038/nm0798-747 · Cited by 238
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
A ribonucleotide reductase gene is a transcriptional target of p53 and p73
Nakano, K., Bálint, É., Ashcroft, M., & Vousden, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203774 · Cited by 233
ASPP1 and ASPP2: Common Activators of p53 Family Members
Bergamaschi, D., Samuels, Y., Jin, B., Duraisingham, S., Crook, T., & Lu, X. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1341-1350.2004 · Cited by 228
Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1
Asher, G., Lotem, J., Sachs, L., Kahana, C., & Shaul, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202480499 · Cited by 220
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T., & Ikawa, S. (2002) · PubMed · Cited by 215
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212 · cited 4×
“p73 protein is also resistant to human papillomavirus (HPV) E6, which together with E6-AP mediates hyperactive degradation of p53 in HPVinfected cells (67, 70).”
BackgroundInfluentialA Dominant-Negative Form of p63 Is Required for Epidermal Proliferation in Zebrafish
Lee, H., & Kimelman, D. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00166-1 · Cited by 209
Frequent alteration of p63 expression in human primary bladder carcinomas.
Park, B.-J., Lee, S. J., Kim, J. I., Lee, S., Lee, C. H., Chang, S. G., Park, J. H., & Chi, S. G. (2000) · PubMed · Cited by 209
TP53 family members and human cancers
Bénard, J., Douc-Rasy, S., & Ahomadegbe, J.-C. (2003) · Human Mutation · doi:10.1002/humu.10172 · Cited by 206
A C-Terminal Inhibitory Domain Controls the Activity of p63 by an Intramolecular Mechanism
Serber, Z., Lai, H. C., Yang, A., Ou, H. D., Sigal, M. S., Kelly, A. E., Darimont, B. D., Duijf, P. H. G., van Bokhoven, H., McKeon, F., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8601-8611.2002 · Cited by 205
Crook, T., Nicholls, J. M., Brooks, L., O'Nions, J., & Allday, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203656 · Cited by 194
Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73
Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6316 · Cited by 193
Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
Zaika, A., Kovalev, S. Y., Marchenko, N. D., & Moll, U. M. (1999) · PubMed · Cited by 191
Self-citationLoss of p73 gene expression in leukemias/lymphomas due to hypermethylation.
Kawano, S., Cw, M., Gombart, A., Bartram, C., Matsuo, Y., Asou, H., Sakashita, A., Said, J. W., Tatsumi, E., & Koeffler, H. P. (1999) · PubMed · doi:10.1182/blood.v94.3.1113.415k33_1113_1120 · Cited by 189
Activation of p73 silent allele in lung cancer.
Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. I., & Liu, W. (1998) · PubMed · Cited by 184
Induction of Neuronal Differentiation by p73 in a Neuroblastoma Cell Line
De Laurenzi, V., Raschellá, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M. V., Tanno, B., Costanzo, A., Levrero, M., & Melino, G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.15226 · Cited by 184
Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients
Casciano, I., Mazzocco, K., Boni, L., Pagnan, G., Banelli, B., Allemanni, G., Ponzoni, M., Tonini, G. P., & Romani, M. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400993 · Cited by 182
Role of p73 in malignancy: tumor suppressor or oncogene?
Stiewe, T., & Pützer, B. M. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400995 · Cited by 178
Nakagawa, T., Takahashi, M., Ozaki, T., Watanabe, K.-I., Todo, S., Mizuguchi, H., Hayakawa, T., & Nakagawara, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2575-2585.2002 · Cited by 178
Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T., Takahashi, T., & Takahashi, T. (1998) · PubMed · Cited by 175
Transactivation-deficient ΔTA-p73 Inhibits p53 by Direct Competition for DNA Binding
Stiewe, T., Theseling, C. C., & Pützer, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200480200 · Cited by 173
Weinstein, M. H., Signoretti, S., & Loda, M. F. (2002) · Modern Pathology · doi:10.1097/01.mp.0000038460.95912.6e · Cited by 172
Promoter specificity and stability control of the p53-related protein p73
Lee, C., & Thangue, N. B. L. (1999) · Oncogene · doi:10.1038/sj.onc.1202793 · Cited by 170
Chi, S.-W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4438 · Cited by 169
Oncogenes Induce and Activate Endogenous p73 Protein
Zaika, A. I., Irwin, M. S., Sansome, C., & Moll, U. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005737200 · Cited by 166
Self-citationTransactivation-deficient DeltaTA-p73 acts as an oncogene.
Stiewe, T., Zimmermann, S., Frilling, A., Esche, H., & Pützer, B. M. (2002) · PubMed · Cited by 163
New p73 variants with altered C-terminal structures have varied transcriptional activities
Ueda, Y., Hijikata, M., Takagi, S., Chiba, T., & Shimotohno, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202817 · Cited by 163
Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma
Tannapfel, A., Wasner, M., Krause, K., Geissler, F., Katalinic, A., Hauss, J., Mossner, J., Engeland, K., & Wittekind, C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1154 · Cited by 163
p53 family genes: structural comparison, expression and mutation
Ikawa, S., Nakagawara, A., & Ikawa, Y. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400631 · Cited by 162
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161 · cited 1×
“MDM2 is transcriptionally activated by p73 and in turn negatively regulates the transcriptional ability of p73, just as it functions toward p53 (67, 72, 73).”
BackgroundDavison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 160
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 156
p63 and p73 Transactivate Differentiation Gene Promoters in Human Keratinocytes
Laurenzi, V. D., Rossi, A., Terrinoni, A., Barcaroli, D., Levrero, M., Costanzo, A., Knight, R. A., Guerrieri, P., & Melino, G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2932 · Cited by 150
Vivarelli, M., Bellusci, R., Cucchetti, A., Cavrini, G., Ruvo, N. D., Aden, A. A., Barba, G. L., Brillanti, S., & Cavallari, A. (2002) · Transplantation · doi:10.1097/00007890-200212270-00017 · Cited by 150
Choi, H.-R., Batsakis, J. G., Zhan, F., Sturgis, E. M., Luna, M. A., & El‐Naggar, A. K. (2002) · Human Pathology · doi:10.1053/hupa.2002.30722 · Cited by 147
Burstein, M., Wu, M., Sabo, M., Wang, B., Miller, P., Gan, M., & Gil, J. (2003) · American Journal of Clinical Pathology · doi:10.1309/p5ab-r5kq-89rn-jtfh · Cited by 147
Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53
Filippovitch, I., Sorokina, N., Gatei, M. H., Haupt, Y., Hobson, K., Moallem, E., Spring, K. J., Mould, M. A., McGuckin, M. A., Lavin, M. F., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204118 · Cited by 145
Nylander, K., Coates, P. J., & Hall, P. A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000801)87:3<368::aid-ijc9>3.0.co;2-j · Cited by 144
p53 associates with and targets ΔNp63 into a protein degradation pathway
Ratovitski, E. A., Patturajan, M., Hibi, K., Trink, B., Yamaguchi, K., & Sidransky, D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1817 · Cited by 142
Overexpression of the wild type p73 gene in human bladder cancer
Yokomizo, A., Mai, M., Tindall, D. J., Liang Cheng, C., Bostwick, D. G., Naito, S., Smith, D. I., & Liu, W. (1999) · Oncogene · doi:10.1038/sj.onc.1202474 · Cited by 139
Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A., Zeillinger, R., Marth, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1060 · Cited by 139
Self-citationElevated expression of p63 protein in human esophageal squamous cell carcinomas
Hu, H., Xia, S., Li, A., Xu, X., Cai, Y., Han, Y., Wei, F., Chen, B., Huang, X., Han, Y., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10739 · Cited by 137
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Shaulsky, G., Goldfinger, N., & Rotter, V. (1991) · PubMed · Cited by 132
Kovalev, S., Marchenko, N. D., Swendeman, S. L., LaQuaglia, M. P., & Moll, U. M. (1998) · PubMed · Cited by 131
Self-citationP63 gene mutations and human developmental syndromes
Brunner, H. G., Hamel, B. C. J., & Bokhoven, H. V. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10778 · Cited by 127 · cited 2×
“There are four additional related human developmental syndromes with p63 mutations (acro-dermato-ungual-lacrimaltooth syndrome, limb mammary syndrome, Rapp-Hodgkin syndrome, and split hand-split foot malformation) that extend the genotype-phenotype correlation (29).”
BackgroundPetrenko, O., Zaika, A. I., & Moll, U. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5540-5555.2003 · Cited by 123
Self-citationIntermediate basal cells of the prostate: In vitro and in vivo characterization
Garraway, L. A., Lin, D. I., Signoretti, S., Waltregny, D., Dilks, J. R., Bhattacharya, N., & Loda, M. F. (2003) · The Prostate · doi:10.1002/pros.10244 · Cited by 112
The Relationship Between p63 and p53 Expression in Normal and Neoplastic Breast Tissue
Ribeiro-Silva, A., Ramalho, L. N. Z., Garcia, S. B., & Zucoloto, S. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-0336-trbpap · Cited by 108
p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation
Katoh, I., Aisaki, K., Kurata, S., Ikawa, S., & Ikawa, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203644 · Cited by 104
Miyazaki, K., Ozaki, T., Kato, C., Hanamoto, T., Fujita, T., Irino, S., Watanabe, K., Nakagawa, T., & Nakagawara, A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01347-0 · Cited by 103
p53 protein variants: structural and functional similarities with p63 and p73 isoforms
Courtois-Cox, S., de Fromentel, C. C., & Hainaut, P. L. (2004) · Oncogene · doi:10.1038/sj.onc.1206929 · Cited by 102
The Survival of Antigen-Stimulated T Cells Requires NFκB-Mediated Inhibition of p73 Expression
Wan, Y. Y., & DeGregori, J. V. (2003) · Immunity · doi:10.1016/s1074-7613(03)00053-0 · Cited by 102
p73 is transcriptionally regulated by DNA damage, p53, and p73
Chen, X., Zheng, Y., Zhu, J., Jiang, J., & Wang, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204149 · Cited by 96
Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas.
Sunahara, M., Ichimiya, S., Nimura, Y., Takada, N., Sakiyama, S., Sato, Y., Todo, S., Adachi, W., Amano, J., & Nakagawara, A. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.2.319 · Cited by 96
Cai, Y., Yang, G., Nie, Y., Wang, L. D., Zhao, X., Song, Y., Seril, D. N., Liao, J., Xing, E. P., & Yang, C. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.683 · Cited by 96
Fomenkov, A., Huang, Y.-P., Topaloglu, O., Brechman, A., Osada, M., Fomenkova, T., Yuriditsky, E., Trink, B., Sidransky, D., & Ratovitski, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300746200 · Cited by 94
P63 expression in normal, hyperplastic and malignant breast tissues
Wang, X., Mori, I., Tang, W., Nakamura, M., Nakamura, Y., Sato, M., Sakurai, T., & Kakudo, K. (2002) · Breast Cancer · doi:10.1007/bf02967592 · Cited by 93
Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins
Steegenga, W. T., Shvarts, A., Riteco, N., Bos, J. L., & Jochemsen, A. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3885 · Cited by 93
Vossio, S., Palescandolo, E., Pediconi, N., Moretti, F., Balsano, C., Levrero, M., & Costanzo, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205465 · Cited by 92
Wienzek‐Lischka, S., Roth, J. C., & Dobbelstein, M. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.193-202.2000 · Cited by 91
Weber, A., Bellmann, U., Bootz, F., Wittekind, C., & Tannapfel, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10296 · Cited by 88
Binding of the C-terminal Sterile α Motif (SAM) Domain of Human p73 to Lipid Membranes
Barrera, F. N., Poveda, J. A., González-Ros, J. M., & Neira, J. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307846200 · Cited by 84
Pignatelli, M., Luna‐Medina, R., PÉREZ-RENDÓN, A., Santos, Á., & Pérez‐Castillo, A. (2003) · Biochemical Journal · doi:10.1042/bj20021918 · Cited by 83
The expression of p73 is increased in lung cancer, independent of p53 gene alteration
Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., 西田, 一., Hayashi, S., Imai, K., Nakachi, K., Ishikawa, Y., Nakagawa, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690572 · Cited by 81
Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells
Sayan, E., Sayan, B. S., Fındıklı, N., & Öztürk, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204669 · Cited by 78
Loss of imprinting and allele switching of p73 in renal cell carcinoma
Mai, M., Qian, C., Yokomizo, A., Tindall, D. J., Bostwick, D. G., Polychronakos, C., Smith, D. I., & Liu, W. (1998) · Oncogene · doi:10.1038/sj.onc.1202099 · Cited by 77
Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma.
Kang, M. J., Park, B.-J., Byun, D.-S., Park, J., Kim, H., Park, J., & Chi, S. G. (2000) · PubMed · Cited by 77
Regulation of p63 Function by Mdm2 and MdmX
Kadakia, M., Slader, C., & Berberich, S. J. (2001) · DNA and Cell Biology · doi:10.1089/10445490152122433 · Cited by 75
Sasaki, Y., Morimoto, I., Ishida, S., YAMASHITA, T., Imai, K., & Tokino, T. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301538 · Cited by 75
ΔN-p73α Accumulates in Human Neuroblastic Tumors
Douc‐Rasy, S., Barrois, M., Echeynne, M., Kaghad, M., Blanc, É., Raguénez, G., Goldschneider, D., Terrier‐Lacombe, M., Hartmann, O., Moll, U. M., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64883-3 · Cited by 75
Self-citationExpression of the vascular endothelial growth factor gene is inhibited by p73
Salimath, B. P., Marmé, D., & Finkenzeller, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203672 · Cited by 73
Prabhu, N. S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., & El-Deiry, W. S. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.1.5 · Cited by 73
Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer.
Chi, S., Chang, S., Lee, S., Lee, C., Kim, J. I., & Park, J. (1999) · PubMed · Cited by 71
A possible role of p73 on the modulation of p53 level through MDM2.
Wang, X. Q., Ongkeko, W. M., Lau, A. W. S., Leung, K. M., & Poon, R. Y. C. (2001) · PubMed · Cited by 70
Gaiddon, C., Lokshin, M., Groß, I., Levasseur, D., Taya, Y., Loeffler, J., & Prives, C. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300251200 · Cited by 70
Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C. L., Cordon‐Cardo, C., & Como, C. J. D. (2003) · PubMed · Cited by 69
Matheny, K. E., Barbieri, C. E., Sniezek, J. C., Arteaga, C. L., & Pietenpol, J. A. (2003) · The Laryngoscope · doi:10.1097/00005537-200306000-00004 · Cited by 67
Analysis of p73 in human borderline and invasive ovarian tumor
Ng, S.-W., Yiu, G. K., Liu, Y., Huang, L., Palnati, M., Jun, S. H., Berkowitz, R. S., & Mok, S. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203512 · Cited by 66
Differential regulation of p63 and p73 expression
Waltermann, A., Kartasheva, N. N., & Dobbelstein, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206859 · Cited by 66
p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma.
Sun, X. (2002) · PubMed · Cited by 64
Dietz, S., Rother, K., Bamberger, C., Schmale, H., Mössner, J., & Engeland, K. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03093-4 · Cited by 64
Identification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation
Gu, J., Chen, D., Rosenblum, J., Rubin, R. M., & Yuan, Z.-M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1243-1253.2000 · Cited by 64
Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer
Tannapfel, A., Schmelzer, S., Benicke, M., Klimpfinger, M., Kohlhaw, K., Mössner, J., Engeland, K., & Wittekind, C. (2001) · The Journal of Pathology · doi:10.1002/path.947 · Cited by 63
Tannapfel, A., Engeland, K., Weinans, L., Katalinic, A., Hauss, J., Mössner, J., & Wittekind, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690465 · Cited by 62
Enhanced p73 Expression during Differentiation and Complex p73 Isoforms in Myeloid Leukemia
Tschan, M. P., Grob, T. J., Peters, U. R., Laurenzi, V. D., Huegli, B., Kreuzer, K., Schmidt, C. A., Melino, G., Fey, M. F., Tobler, A., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3627 · Cited by 62
p73 competes with p53 and attenuates its response in a human ovarian cancer cell line
Vikhanskaya, F., D'Incalci, M., & Broggini, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.2.513 · Cited by 58
Adenovirus‐mediated Transfer of p53‐related Genes Induces Apoptosis of Human Cancer Cells
Ishida, S., Yamashita, T., Nakaya, U., & Tokino, T. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00929.x · Cited by 57
Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73
Higashino, F., Pipas, J. M., & Shenk, T. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15683 · Cited by 54
p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement.
Rödicker, F., & Pützer, B. M. (2003) · PubMed · Cited by 53
P73 gene expression in ovarian cancer tissues and cell lines.
Chen, C., Ip, S.-M., Cheng, D., Wong, L. C., & Ngan, H. (2000) · PubMed · Cited by 53
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
Novak, U., Grob, T. J., Baskaynak, G., Peters, U. R., Aebi, S. P., Zwahlen, D. R., Tschan, M. P., Kreuzer, K., Leibundgut, E. O., Cajot, J., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011153206003 · Cited by 53
Ozaki, T., Watanabe, K., Nakagawa, T., Miyazaki, K., Takahashi, M., & Nakagawara, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206382 · Cited by 52
Stiewe, T., Stanelle, J., Theseling, C. C., Pollmeier, B., Beitzinger, M., & Pützer, B. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300357200 · Cited by 48
p73 Is Regulated by Phosphorylation at the G2/M Transition
Fulco, M., Costanzo, A., Merlo, P., Mangiacasale, R., Strano, S., Blandino, G., Balsano, C., Lavia, P., & Levrero, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304921200 · Cited by 45
p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner
Zhu, J., Nozell, S. E., Wang, J., Jiang, J., Zhou, W., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204516 · Cited by 45
Peters, U. R., Tschan, M. P., Kreuzer, K., Baskaynak, G., Lass, U., Tobler, A., Fey, M. F., & Schmidt, C. A. (1999) · PubMed · Cited by 43
Failure of viral oncoproteins to target the p53-homologue p51A
Roth, J. C., & Dobbelstein, M. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-12-3251 · Cited by 43
Slade, N., Zaika, A. I., Erster, S. H., & Moll, U. M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401335 · Cited by 40
Self-citationDifferential expression of p73 splice variants and protein in benign and malignant ovarian tumours
Zwahlen, D. R., Tschan, M. P., Grob, T. J., Peters, U. R., Fink, D. A., Hænggi, W., Altermatt, H. J., Cajot, J., Tobler, A., Fey, M. F., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001001)88:1<66::aid-ijc10>3.0.co;2-y · Cited by 39
Characterization of p73 functional domains necessary for transactivation and growth suppression
Nozell, S. E., Wu, Y., McNaughton, K., Liu, G., Willis, A. C., Paik, J. C., & Chen, X. (2003) · Oncogene · doi:10.1038/sj.onc.1206470 · Cited by 37
p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma
Guan, M. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg045 · Cited by 35
Wu, M., Wang, B., Gil, J., Sabo, E., Miller, L. K., Gan, L., & Burstein, D. (2003) · American Journal of Clinical Pathology · doi:10.1309/xcp6ewpbg3bmrka · Cited by 35
Kaida, A., Ariumi, Y., Ueda, Y., Lin, J.-Y., Hijikata, M., Ikawa, S., & Shimotohno, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203387 · Cited by 35
Herranz, M., Santos, J., SALIDO, E. C., Fernández‐Piqueras, J., & Serrano, M. (1999) · PubMed · Cited by 31
Structure of the C-terminal sterile α-motif (SAM) domain of human p73α
Wang, W. K., Bycroft, M., Foster, N. W., Buckle, A. M., Fersht, A. R., & Chen, Y. W. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901002529 · Cited by 31
Modulation of p53 function in cellular regulation
Appella, E. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02224.x · Cited by 31
Zeng, X., Zhu, Y., & Lu, H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.215 · Cited by 24
The yeast two-hybrid system reveals no interaction between p73α and SV40 large T-antigen
Reichelt, M., Zang, K. D., Seifert, M., Welter, C., & Ruffing, T. L. (1999) · Archives of Virology · doi:10.1007/s007050050530 · Cited by 11
Cited by
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
Teschendorff, A. E., Menon, U., Gentry-Maharaj, A., Ramus, S. J., Weisenberger, D. J., Shen, H., Campan, M., Noushmehr, H., Bell, C. G., Maxwell, A. P., et al. (2010) · Genome Research · doi:10.1101/gr.103606.109 · Cited by 855
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Regulation of gene-activation pathways by PIAS proteins in the immune system
Shuai, K., & Liu, B. (2005) · Nature Reviews Immunology · doi:10.1038/nri1667 · Cited by 447
Metadata
- Authors
- Moll, U. M., & Slade, N.
- Venue
- Molecular Cancer Research
- Published
- 2004-07-01
- Volume
- 2
- Issue
- 7
- Pages
- 371-386
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2313048860
- Cited by
- 486
- References
- 166
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.